# Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

> **NCT04806893** · PHASE3 · UNKNOWN · sponsor: **LIB Therapeutics LLC** · enrollment: 900 (estimated)

## Conditions studied

- Cardiovascular Risk Factor
- Cardiovascular Diseases
- Cardiovascular Stroke
- Hypercholesterolemia

## Interventions

- **DRUG:** lerodalcibep
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04806893
- **Lead sponsor:** LIB Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-22
- **Primary completion:** 2023-11-15
- **Final completion:** 2024-02-28
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2023-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04806893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04806893, "Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04806893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*